TOWARD PACLITAXEL-(60)FULLERENE IMMUNOCONJUGATES AS A TARGETED PRODRUG AGAINST CANCER

Abstract

Two newly synthesized water-soluble conjugates of Paclitaxel with malonodiserinolamide-derivatized [60]fullerene (C60-ser) undergo hydrolysis and release their medical payload under biological conditions. In vivo testing of one of these compounds in a murine model showed tumor volume reduction similar to the FDA-approved drug Abraxane, but without the associated weight-loss, indicating better tolerance of this new formulation.